Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia Meeting Abstract
| Authors: | O'Brien, S.; Patel, M.; Kahl, B. S.; Horwitz, S. M.; Foss, F. M.; Porcu, P.; Sweeney, J.; Allen, K.; Faia, K.; Stern, H. M.; Kelly, P.; Flinn, I. |
| Abstract Title: | Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349242707016 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.3334.3334 |
| Notes: | Meeting Abstract: 3334 -- Source: Wos |
